TROP-2 in NSCLC

CME

Antibody‒Drug Conjugates Targeting TROP-2 in NSCLC: A Look to the Future

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: July 25, 2023

Expiration: July 24, 2024

Hossein Borghaei
Hossein Borghaei, MS, DO
Rebecca S. Heist
Rebecca S. Heist, MD, MPH
Melissa L. Johnson
Melissa L. Johnson, MD
Benjamin Levy
Benjamin Levy, MD
Stephen V. Liu
Stephen V. Liu, MD

Activity

Progress
1
Course Completed

Introduction

In this module, Stephen Liu, MD, leads a discussion with his colleagues—Hossein Borghaei, MS, DO; Rebecca S. Heist, MD, MPH; Melissa L. Johnson, MD; and Benjamin Levy, MD—about the current state and future of TROP-2‒directed therapy for patients with non-small-cell lung cancer (NSCLC). First, they review the basics of antibody‒drug conjugates (ADCs), including mechanism of action. Next, they discuss the basis of TROP-2 as a target for lung cancer therapy. Finally, they describe the latest clinical data with TROP-2‒directed ADCs, including efficacy, safety, and optimal treatment strategies for NSCLC.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking any of the slide thumbnails in the module alongside the expert commentary. 

Clinical Care Options plans to measure the educational impact of this activity. Some questions will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

For those providing patient care, how many patients with NSCLC do you provide care for in a typical month?

Which of the following most accurately describes features of datopotamab deruxtecan and sacituzumab govitecan-hziy, the 2 TROP-2‒targeted ADCs that are being evaluated in patients with NSCLC?

Based on current evidence, what level of TROP-2 tumor expression by immunohistochemistry is required for patients with NSCLC to be considered candidates for treatment with a TROP-2-targeted ADC on a trial?

A patient on a clinical trial with datopotamab deruxtecan notes mild dry cough and occasional chest discomfort when asked about these symptoms. Pneumonitis is suspected. In addition to obtaining imaging, which of the following is the best next step?